JP
RARE icon

Jana Partners’s Ultragenyx Pharmaceutical RARE Stock Holding History

Jana Partners’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-128,121
Closed -$9.01M – 61
2016
Q4 		$9.01M Buy
128,121
+47,996
+60% +$3.41M 0.16% 37
2016
Q3 		$5.68M Buy
+80,125
New +$5.11M 0.1% 34

Other funds holding RARE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
CGT
Capital Guardian Trust Los Angeles, California $7.42B AUM 13.6% 1-Year Est. Return

Jana Partners's RARE Position: Q1 2017 in Review

Jana Partners sold out of Ultragenyx Pharmaceutical (RARE) in Q1 2017, closing a stake of 128,121 shares — an estimated $9.01M sold.

Jana Partners first reported a position in RARE in Q3 2016 and held it in 2 quarters. The position peaked at $9.01M in Q4 2016. 164 funds tracked by Wall St. Rank hold RARE as of Q1 2017.

  • Jana Partners reported no remaining Ultragenyx Pharmaceutical position as of Q1 2017 after selling out during the quarter.
  • Jana Partners sold 128,121 Ultragenyx Pharmaceutical shares in Q1 2017, an estimated $9.01M.
  • Jana Partners first reported a position in Ultragenyx Pharmaceutical in Q3 2016 and held it in 2 quarters.
  • Jana Partners's Ultragenyx Pharmaceutical position peaked at $9.01M in Q4 2016.
  • 164 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2017.

Based on Jana Partners's 13F filing for Q1 2017, filed 15 May 2017.